Back to top
more

Organogenesis (ORGO)

(Delayed Data from NSDQ)

$4.56 USD

4.56
1,386,401

+0.04 (0.77%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $4.56 +0.01 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 244)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Organogenesis (ORGO) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 412.50% and 3.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Stock Jumps 7.4%: Will It Continue to Soar?

by Zacks Equity Research

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Is Abbott (ABT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Abbott (ABT) and Organogenesis (ORGO) have performed compared to their sector so far this year.

Zacks Equity Research

Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 50.00% and 1.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Organogenesis (ORGO) closed the most recent trading day at $11.44, moving +0.53% from the previous trading session.

Zacks Equity Research

Analysts Estimate Organogenesis (ORGO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.

Zacks Equity Research

Organogenesis (ORGO) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Organogenesis (ORGO) closed the most recent trading day at $10.98, moving +0.64% from the previous trading session.

Zacks Equity Research

Zacks.com featured highlights include: SunOpta, Citi Trends, Organogenesis, Tapestry and Venus Concept

by Zacks Equity Research

Zacks.com featured highlights include: SunOpta, Citi Trends, Organogenesis, Tapestry and Venus Concept

Sanghamitra Saha headshot

Forget Bargains, Play 5 Stocks with Rising P/E Instead

by Sanghamitra Saha

Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

Zacks Equity Research

Can Organogenesis (ORGO) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Organogenesis (ORGO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 114.29% and 16.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

by Zacks Equity Research

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

Kinjel Shah headshot

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

by Kinjel Shah

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in the second quarter of 2021. However, with demand trends expected to improve, XNCR, ORGO, CPIX, and ACER may prove to be good additions to one's portfolio.

Zacks Equity Research

Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review

by Zacks Equity Research

Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.

Zacks Equity Research

Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed

by Zacks Equity Research

Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.

Zacks Equity Research

Organogenesis (ORGO) Stock Jumps 7.7%: Will It Continue to Soar?

by Zacks Equity Research

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 275.00% and 18.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis Holdings' (ORGO) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Organogenesis Holdings (ORGO).

Zacks Equity Research

Organogenesis (ORGO) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 25.00% and 1.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What's in Store for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Equity Research

Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics

by Zacks Equity Research

Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics